ClinicalTrials.gg

Program

delocamten

Also written as “BMS-986435” and “MYK-224”.

Its studies are mostly in Heart Failure · Cardiomyopathy, Hypertrophic, led by Bristol-Myers Squibb.

Furthest: phase 2, since Sep 23, 20229 company-led studies, 2 open or runningNext primary completion: Dec 14, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb92 open or runningphase 2since Sep 23, 2022Mar 22, 2022Dec 14, 2026phase 2 · NCT06122779
  • Named in Bristol-Myers Squibb’s own pipeline as delocamten, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2022First study: phase 1 study in Healthy ParticipantsFirst studyNCT05304533 · 45 enrolled · United States
  2. Jun 1, 2022Phase 1 study in Healthy VolunteersNCT05405543 · 36 enrolled · United States
  3. Sep 23, 2022Phase 2 study in Cardiomyopathy, HypertrophicNCT05556343 · 18 enrolled · United States, Italy, Poland and more
  4. Jan 6, 2023Phase 1 study in Healthy VolunteersNCT05686096 · 7 enrolled · United States
  5. Nov 3, 2023Phase 2 study in Heart FailureNCT06122779 · 227 enrolled · United States, Argentina, Canada and more
  6. Jun 21, 2024Phase 1 study in Healthy VolunteersNCT06476821 · 20 enrolled · China
  7. Aug 27, 2024Phase 1 study in Healthy ParticipantsNCT06577259 · 25 enrolled · United States
  8. Nov 7, 20252 phase 1 studies in Healthy VolunteersNCT07226817, NCT07248839

Ahead

  1. Dec 14, 2026Primary completion: phase 2 study in Heart FailureNCT06122779
  2. Dec 17, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07226817

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07248839Healthy Volunteers · United States1CompletedAug 20, 202669
NCT07226817Healthy Volunteers · United States1RecruitingDec 17, 2026240
NCT06577259Healthy Participants · United States1CompletedFeb 19, 202525
NCT06476821Healthy Volunteers · China1CompletedOct 11, 202420
NCT06122779Heart Failure · United States, Argentina, Canada and more2Active, not recruitingDec 14, 2026227
NCT05686096Healthy Volunteers · United States1CompletedApr 8, 20237
NCT05556343Cardiomyopathy, Hypertrophic · United States, Italy, Poland and more2TerminatedAug 19, 202418
NCT05405543Healthy Volunteers · United States1CompletedNov 16, 202236
NCT05304533Healthy Participants · United States1CompletedNov 14, 202245

How it is read

Names in the registry

  • “BMS-986435”, 5 entries
  • “MYK-224”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.